Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy (GT): Updated Results in Group C Patients from the Phase 1/2 Hgb-206 Study | Zendy

Mark C. Walters | Zendy; Julie Kanter | Zendy; Janet L. Kwiatkowski | Zendy; Lakshmanan Krishnamurti | Zendy; Markus Y. Mapara | Zendy; Manfred Schmidt | Zendy; Alexandra L. Miller | Zendy; Jr. Francis J. Pierciey | Zendy; Melissa Bonner | Zendy; Wenmei Huang | Zendy; JeanAntoine Ribeil | Zendy; Alexis A. Thompson | Zendy; John F. Tisdale | Zendy

Open Access

Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy (GT): Updated Results in Group C Patients from the Phase 1/2 Hgb-206 Study

Author(s) -

Mark C. Walters,

Julie Kanter,

Janet L. Kwiatkowski,

Lakshmanan Krishnamurti,

Markus Y. Mapara,

Manfred Schmidt,

Alexandra L. Miller,

Jr. Francis J. Pierciey,

Melissa Bonner,

Wenmei Huang,

JeanAntoine Ribeil,

Alexis A. Thompson,

John F. Tisdale

Publication year - 2020

Publication title -

biology of blood and marrow transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.301

H-Index - 120

eISSN - 1523-6536

pISSN - 1083-8791

DOI - 10.1016/j.bbmt.2019.12.136

Subject(s) - medicine , plerixafor , apheresis , cd34 , peripheral blood mononuclear cell , adverse effect , hemoglobin , haematopoiesis , fludarabine , bone marrow , gastroenterology , hematopoietic stem cell transplantation , busulfan , cyclophosphamide , immunology , urology , platelet , transplantation , stem cell , cxcr4 , chemotherapy , biochemistry , chemistry , chemokine , receptor , biology , in vitro , genetics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research